Table 4– Sample entropy (SampEn) of impedance measurements in healthy subjects and patients with asthma
SampEn R5R20SampEn AXSampEn R20
Healthy controls
 Baseline0.008 (0.001–0.025)0.42 (0.22–0.81)0.025 (0.007–0.044)
 Post-BD0.004 (0.001–0.021)0.39 (0.19–0.59)0.021 (0.007–0.060)
Asthma
 GINA step 4
  Baseline0.042 (0.003–0.100)**1.05 (0.47–1.27)##0.079 (0.017–0.156)
  Post-BD0.027 (0.007–0.069)0.80 (0.52–1.08)0.038 (0.020–0.133)
 GINA step 5
  Baseline0.150 (0.055–0.300)###1.19 (0.80–1.45)###0.129 (0.053–0.291)###
  Post-BD0.094 (0.017–0.190)¶¶1.09 (0.69–1.37)0.096 (0.036–0.283)
  • Data are presented as median (interquartile range). R5R20: resistance at 5 Hz minus resistance at 20 Hz; AX: reactance area; R20: resistance at 20 Hz; BD: bronchodilator; GINA: Global Initiative for Asthma. **: p<0.01 between GINA step 4 and GINA step 5 groups (using Kruskal–Wallis test with Dunn’s correction); ##: p<0.01 compared with control group (using Kruskal-Wallis test with Dunn’s correction); ###: p<0.001 compared with control group (using Kruskal-Wallis test with Dunn’s correction); : p<0.05 compared with baseline (using Friedman’s test with Dunn’s correction); ¶¶: p<0.01 compared with baseline (using Friedman’s test with Dunn’s correction).